Showing posts with label alzheimer's disease. Show all posts
Showing posts with label alzheimer's disease. Show all posts

Tuesday, June 18, 2013

New Randomized Double-Blind Trial in the Works With EGCG

Richard over at the DSTNI listserv, shared the following:


I just found out that a second and larger clinical trial has started in Spain. The dosage remains the same as in the pilot study, but this time the duration was set for 12 instead of only 3 months, and there are 100 participants ages 14 to 29yrs. First results are expected for December 2013.
The name of the clinical trial is: Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool.

This is the brief summary and the goal of the study:

Epigallocatechin-3-gallate (EGCG), the major catechin in green tea, is postulated to modulate dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) and amyloid beta precursor protein (APP) gene overexpression in the brains of Down syndrome mouse models. The clinical study is aimed at demonstrating that normalization of Dyrk1A and APP functions is a therapeutic approach to improve cognitive performance and decelerate AD (Alzheimer's disease) like progression.
You can see the full clinical trial page at http://clinicaltrials.gov/ct2/show/record/NCT01699711.

Country Girl Designs

Sunday, March 24, 2013

Green Tea Extract: EGCG & The Benefits It Has for Down Syndrome


EGCG, which stands for Epigallocatechin-3-gallate, is an extract from Green Tea. EGCG is the major polyphenolic compound found in green tea. Green Tea has been known to have lots of health benefits for awhile, but about two years ago it came to the attention of people in the Down syndrome world.

I’ve been watching it over the last couple years. But, when I saw some new research come out about EGCG a couple weeks ago, I decided it was time to jump on the bandwagon and start supplementing with EGCG. As usual though, I needed to have all my ducks in a row, so to speak, have all the research and facts lined up, so I can definitively know why we are using EGCG. Of course, this helps others as well, which is also why I’ve typed it all up.

Original research with EGCG that sparked the attention of those in the DS world was research for Alzheimer’s disease. Let’s look at some of this initial research to lay the groundwork.

EGCG prevents certain apoptotic (pre-programmed) cell death through inhibiting the elevation of Abeta (a protein involved with Alzheimer’s and also involved with DS) via inhibition of beta and gamma-secretases. This, therefore, reduces neuroinflammation that’s associated with the progression of Alzheimer’s disease (1). We also know that neuroinflammation is involved with DS.

Alzheimer’s Disease & Down syndrome have the increased amyloid-beta protein (Abeta), which causes plaques & tangles in the brain. The processes & increases which Abeta cause are reduced by EGCG. EGCG improves memory function, as well as reducing harmful levels of increased Abeta and its associated functions (2).

So, we have EGCG which prevents cell death, reduces the elevated levels of amyloid beta, reduces Beta Secretase expression, reduces APP (Amyloid Precursor Protein – overexpressed in DS) and reduces neuroinflammation. All of this will help improve neurogenesis. That’s all great stuff, but there’s still more amazing benefits to EGCG – specifically for Down syndrome.

There’s an annoying little gene that is over expressed in Down syndrome called – get ready for this long word - dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A, also known as DYRK1A. We’ll use the abbreviated word, since it’s a lot easier to say and remember! DYRK1A causes cognitive & learning impairments in DS and is highly involved in the neurodegenerative process in the Down syndrome brain (3-6). It also plays a role in the Alzheimer-like pathway that is seen in Down syndrome (3).
The good thing about DYRK1A is research has shown that it can be inhibited. If DYRK1A is inhibited, then the harmful effects of the gene won’t be able to function.  Remember, the over expressed aspect of this gene is what is the problem – not just the gene in and of itself.

EGCG is a safe DYRK1A inhibitor and there has been very successful research done in individuals with Down syndrome. The Jerome Lejeune Foundation has a program designed to research what will inhibit this gene. Professor Mara Dierssen, from the Jerome Lejeune Foundation, has had a very successful clinical trial (10) with individuals with Down syndrome using EGCG. Professor Dierssen is also now recruiting for a second clinical trial (11).

EGCG is also a GABA antagonist (7-9). An antagonist is a substance that acts within the body to reduce the physiological activity of another substance. Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter.

Now that we have the definitions down, let’s get on to the problem with GABA. GABA is a good thing when it is not in excess, because it creates the perfect balance between neuronal excitation and inhibition to allow for efficient learning. But, there appears to be too much GABA-related inhibition in Down syndrome and therefore it “turns off” too many neurons in the brain and makes it more difficult to process information.

So, EGCG being a GABA antagonist, namely blocking the GABA(A) receptor (recombinant alpha1beta2gamma2L GABA(A) receptor), is a very beneficial thing for individuals with DS.  Having an antagonist which can reduce GABA, will greatly help the brain and learning in Down syndrome.

Mitochondrial dysfunction has been well established in Down syndrome. EGCG prevents oxidative deficit in the mitochondria, reduces oxidative stress and actually promotes mitochondrial biogenesis in Down syndrome (12).  This is amazing, because there has never before, to my knowledge, been a way to efficiently combat the mitochondrial dysfunction in Down syndrome.

EGCG is also an iron-chelator, which can be beneficial for individuals with DS, due to the oxidation issues that come with high levels of iron. Now, if an individual with DS already has low levels of iron, this would be something to keep in mind and monitor the iron levels while supplementing with EGCG.
So, to recap, EGCG helps improve memory, reduce the learning impairment seen in individuals with DS, reduce oxidative stress, is a potent antioxidant, promotes mitochondrial biogenesis, is a GABA antagonist, is an iron-chelator, inhibit DYRK1A, prevents cell death, reduces neuroinflammation, reduces Beta Secretase & APP expression, and causes a reduction in Abeta and the problems it causes.

With all this, one may ask, is there anything negative about EGCG? There is one thing to keep an eye on, but I wouldn’t necessarily call it a “negative.”

EGCG inhibits or reduces DHFR, which is an enzyme involved in the methylation and folate cycle. So, ultimately, it may reduce folate. We already know that folate is reduced in Down syndrome and many people use additional supplements to increase folate in Down syndrome. As long as a sufficient amount of folate or folinic acid is supplemented, I would not be too concerned about this aspect of EGCG. There are some other questions regarding DHFR and some genes that it is involved in regulating – whether it is good to stop that or not.

But, for now, look at all the benefits for EGCG above and think about all the problems which DYRK1A (and others) cause. The answer is simple for me, at the moment: Supplement with additional folate/folinic acid, or supplements to support the methylation cycle, as you are using EGCG.

Now, the question comes down to, what is the recommended dosage and what are the best brands.

The recommended dosage is 9mg/kg (kg=2.5lbs) of EGCG. This is the dosage that the clinical trials in Down syndrome are using. This is also the dosage that many parents are using with their children.

One important note on the dosage: that is NOT 9mg/kg of Green Tea. This is important to note, as most products will be Green Tea that you are giving. You will have to calculate the amount of EGCG in the product to give the correct amount. You will be giving more Green Tea, but the recommended dosage of 9mg/kg.

Because EGCG is still in the early stages of use and development, it can be a little tricky to get a brand that is bioavailable. A good brand of just EGCG is Teavigo. The problem with Teavigo is that it is not in a liposomal encapsulation (a fatty acid), to make it bioavailable enough to cross the blood-brain-barrier (which is where it is needed).

GreenSelect Phytosomes made by a company named Indena, has been found by some to be a good bioavailable form of EGCG. This has the phospholipid bound to it. There are several companies which use GreenSelect as their base. One example is VitaCost GreenSelect. Another example is Swanson's Ultra GreenSelect Green Tea Phytosome.

Another liposomal brand which some families use with their children is Enzymatic Therapy Green Tea Elite with EGCG. You can view it here and here.

We will be using the Swanson's Ultra GreenSelect Green Tea Phytosome, as is mentioned above. The cost is $14.99 for 60 capsules. Each capsule contains the following:

GreenSelect® Phytosome™
(green tea extract Camellia sinensis leaves/ Glycine max soybeans) -600 mg
Standardized to:  
19-25% polyphenols - 114-150 mg  
13% epigallocatechin 3-0 gallate (EGCG) - 78 mg
The dosage can be a little tricky with the GreenSelect Green Tea. VitaCost's GreenSelect Extract which is mentioned above contains the following per 1 capsule:
“Green Tea Extract (Camellia sinensis leaves/Glycine max soybeans) [standardized to 60% polyphenols 180mg, 40% epigallocatechin 3-0 gallate (EGCG) 120 mg]”
Originally we were going to use the VitaCost brand. But, Richard on the DSTNI list pointed out that VitaCost doesn't calculate the dosage accurately. Yes, it can be a little confusing. But, they miss the dosage part of the fatty acids in the mix. So, the dosage above for Swanson's GreenSelect is accurate and not as confusing. The VitaCost dosage is not accurate.

For a child that is O’s weight – 50 lbs – that would calculate out to 180mg/day of EGCG. With the Swanson GreenSelect EGCG, that would mean approximately 2 & 1/2 capsules. With the VitaCost brand, the dosage is almost doubled.

So, there’s a LONG explanation of why EGCG is good and everything that goes with it. I will keep notes of how O does on the EGCG and any changes we see.

*Note (Update 8/20/15): I realized that it is not mentioned about giving the child the 9mg/kg dosage of EGCG twice a day. That IS the recommended thing to do. It is best to give the 9mg/kg dosage TWICE a day, as then it is in child's body at all times. We do this with O. Some have had problems giving the dosage at night, because it has kept their child awake. Others have not had this problem. We have not experienced this problem at all.

References:
1. Brain Res. 2009 Jan 23;1250:164-74 (-)-Epigallocatechin-3-gallate prevents lipopolysaccharide-induced elevation of beta-amyloid generation and memory deficiency. Lee YK, Yuk DY, Lee JW, Lee SY, Ha TY, Oh KW, Yun YP, Hong JT.
2. Nutr. 2009 Oct;139(10):1987-93. Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappaB pathways in mice. Lee JW, Lee YK, Ban JO, Ha TY, Yun YP, Han SB, Oh KW, Hong JT.
3. Ageing in Down Syndrome: DYRK1A As a Candidate Gene for Cognitive Decline
http://www.sciencedirect.com/science/article/pii/S2171974808700394
4. Dyrk1A Overexpression Inhibits Proliferation and Induces Premature Neuronal Differentiation of Neural Progenitor Cells. http://www.jneurosci.org/content/30/11/4004.full
5. DYRK1A in normal brain development and Down syndrome. http://www.nature.com/nrn/journal/v13/n12/fig_tab/nrn3314_F2.html 
6. Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0004606
7. http://sydney.edu.au/medicine/pharmacology/adrien-albert/images/pdfs/RefsPDFs/367.pdf 
8. Reducing GABAA α5 Receptor-Mediated Inhibition Rescues Functional and Neuromorphological Deficits in a Mouse Model of Down Syndrome. http://www.jneurosci.org/content/33/9/3953.full
9. Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease. http://www.ncbi.nlm.nih.gov/pubmed/21388375
10. http://clinicaltrials.gov/ct2/show/NCT01394796?term=EGCG+and+down+syndrome&rank=1
11. http://clinicaltrials.gov/ct2/show/NCT01699711?term=EGCG+and+down+syndrome&rank=2
12. Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndrome http://www.sciencedirect.com/science/article/pii/S092544391200302X
13.  A few helpful websites:
https://sites.google.com/site/superdownsyndrome/supplements/green-tea-extract
http://changingmindsaboutdownsyndrome.blogspot.com (search EGCG)
http://dsdaytoday.blogspot.com/2011/03/egcg-green-tea-extract.html
http://dstoner.net/Math_Science/Downs.html




Country Girl Designs


Wednesday, October 31, 2012

31 for 21: Oxidative Stress & Down Syndrome

Well, 31 for 21 is coming to a close. I didn't get nearly as many "in-depth" posts up as I may have liked. So, I'll just have to work on that over the next few months :).

Today, I wanted to share a study that came across a DS listserv the other day on Oxidative Stress and Down syndrome.

Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia

You can view the full text of the report here.

I wanted to point out a few quotes from the conclusion.

It's already a well established fact that there is increased oxidative stress in Down syndrome, just like this points out.

"Within the context of the reported findings discussed above, we hypothesize that trisomy affects gene/protein expression that results in increased OS conditions and impaired mitochondrial function. These alterations occur early in DS as demonstrated by studies performed on fetal brain and amniotic fluid from DS pregnancy and play an important  role in neurodegeneration."





This is true below and a lot of people may not realize it. It's not just that the overexpression of SOD1 causes increased oxidative stress. It also reduces levels of agents that would counter act that oxidative stress and lowers the antioxidant enzymes.
"OS conditions arise not only from overexpression of SOD1 but also as a consequence of low levels of reducing agents and antioxidant enzymes."
Just thought this was an interesting statement:
"It is now well accepted that OS contribute to neurodegeneration, but in the case of DS and AD, genetic similarities, due to the fact that some of the genes responsible for familial form of AD are encoded by Chr21, provide an interesting field of research for the comprehension of many yet unsolved issues."
This is exactly why targeted nutritional intervention is so entirely important for individuals with DS. We have to combat the low antioxidant levels in DS with plenty of antioxidants!
"Based on this notion, it is possible that using antioxidant nutrients to scavenge oxygen-derived free radicals may modulate some of the complications of DS. "



Country Girl Designs

Wednesday, August 3, 2011

Antioxidants & Dementia

A new study came out recently on individuals with Down syndrome who had dementia. The study was looking at antioxidant supplementation to combat dementia. I will paste the study here and comment below it.


Down syndrome and dementia: A randomized, controlled trial of antioxidant supplementation.
Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DL.
Am J Med Genet A. 2011 Aug.
Department of Pediatrics, School of Medicine, University of California, Irvine (UCI), Orange, California; Department of Neurology, School of Medicine, University of California, Irvine (UCI), Irvine, California. itlott@uci.edu.


Individuals with Down syndrome over age 40 years are at risk for developing dementia of the Alzheimer type and have evidence for chronic oxidative stress. There is a paucity of treatment trials for dementia in Down syndrome in comparison to Alzheimer disease in the general (non-Down syndrome) population. This 2-year randomized, double-blind, placebo-controlled trial assessed whether daily oral antioxidant supplementation (900 IU of alpha-tocopherol, 200 mg of ascorbic acid and 600 mg of alpha-lipoic acid) was effective, safe and tolerable for 53 individuals with Down syndrome and dementia. The outcome measures comprised a battery of neuropsychological assessments administered at baseline and every 6 months. Compared to the placebo group, those individuals receiving the antioxidant supplement showed neither an improvement in cognitive functioning nor a stabilization of cognitive decline. Mean plasma levels of alpha-tocopherol increased ∼2-fold in the treatment group and were consistently higher than the placebo group over the treatment period. Pill counts indicated good compliance with the regimen. No serious adverse events attributed to the treatment were noted. We conclude that antioxidant supplementation is safe, though ineffective as a treatment for dementia in individuals with Down syndrome and Alzheimer type dementia. Our findings are similar to studies of antioxidant supplementation in Alzheimer disease in the general population. The feasibility of carrying out a clinical trial for dementia in Down syndrome is demonstrated. © 2011 Wiley-Liss, Inc.

So, this study used 900IU of Vitamin E, 200mg of Vitamin C and 600mg of Alpha-Lipoic Acid (ALA).

First of all, those doses are pretty low, particularly for people who already have dementia. It's very, very late to start treatment, although it could still help.

While this study didn't find any changes in the dementia of these patients, they did find an increase in Vitamin E levels by 2-fold in the treatment group. That, in and of itself, is going to help greatly.

Knowing what we do know about Vitamin E and it's antioxidant effects, if the treatment is started early enough (in childhood), it's very likely to be able to prevent dementia.

I find it quite silly for the conclusion of the study to say that "antioxidant supplementation is safe, though ineffective as a treatment for dementia in individuals with Down syndrome." Well, when you already have people with DS who have dementia, don't ya think it's kind of late in the game to treat it? It's already caused SO much irreversible damage. The "treatment for dementia" should be started a whole lot earlier than that. Early as in the childhood years.

From what I know through other research and in talking with other doctors, especially Dr. Leichtman, antioxidant supplementation, if started early enough can and does prevent dementia.

In reality, it's never too late to start antioxidant supplementation, but the earlier you start it, the better. The less damage that will be done. Damage that can be irreversible.

Dr. Leichtman, has been working with people with Down syndrome of all ages for many, many years now. He has specifically been working with them with nutritional (antioxidant) supplementation. One of his comments in regards to this study is below. It is encouraging for those who have young children who are just starting Nutrivene or an antioxidant program, because it really does work.

In an ideal world where we can get everyone with DS supplemented young, the younger the better. I can document it holds off degeneration for a long time. I still see people who were placed on the old Turkel protocol 30-40 years ago and are now on NVD protocol and none of them have dementia so I know this works.

That's why I encourage any new family to start your child on at least Nutrivene as early as you possibly can. Oxidative stress starts to take hold while the baby is in utero and it only increases from there, if nothing is done about it.


Country Girl Designs

Tuesday, June 14, 2011

Down Syndrome Brain & Norepinephrine drugs

I recently received an email from a family with questions regarding the supplements they were using and considering using with their young daughter with Down syndrome. A couple of the supplements that were in the email, I didn't know very much about and hadn't heard of before. So, of course I wanted to research it to be able to share what I found with them and to also know what it is used for, in case it is something we would consider for my little brother.

In Down syndrome there are several concerns with problems in the brain and degeneration in certain parts of the brain. One area of the brain which sees degeneration is the locus coeruleus (LC), which is in the brainstem. LC supplies the hippocampus with norepinephrine (NE), also known as noradrenaline, which is a neurotransmitter that nerve cells use to communicate. The hippocampus also is affected in people with Down syndrome. This degeneration and lack of NE to the hippocampus creates memory problems. As is described in this quote from Stanford University's article,

"Salehi and his colleagues looked at what could be causing the problems in the hippocampus. Normally, as contextual or relational memories are formed, hippocampal neurons receive norepinephrine from neurons in another part of the brain, the locus coeruleus. The researchers showed that, like humans with Down syndrome, the mice in their experiments experienced early degeneration of the locus coeruleus.
 When the locus coeruleus broke down in the study’s mice, the animals failed at simple cognitive tests that required them to be aware of changes in the milieu: For instance, the genetically engineered mice, when placed in the strange environment of an unknown cage, did not build nests. That contrasts with normal mice, which typically build nests in such circumstances."
As is briefly mentioned in the quote above, near the end of 2009 Stanford University's researchers studied LC, low amounts of NE and it's role in the hippocampus and how to positively change the neurodegeneration.

In this study done by researcher Salehi, they used a "pro-drug" (i.e. it's pro towards norepinephrine) to increase the amounts of NE in the brain of mice models of DS. Their results were very good, as can be seen by a quote from the full text of the study (which can be viewed here),
"In this study, we linked marked defects in hippocampally mediated contextual learning in a model of DS to LC dysfunction and demonstrated that these deficits can be restored by treatments targeted at correcting deficient NE neurotransmission."
So, in short, the researchers used a "pro-drug" called Droxidopa (L-threo-dihydroxyphenylserine, L-DOPS) to increase NE levels in the brain.

Droxidopa crosses the Blood-Brain-Barrier (BBB) and then is able to be used where it is most needed.  Droxidopa was used in conjunction with Carbidopa (which is a DOPA decarboxylase inhibitor). Carbidopa is necessary to be given with Droxidopa so that Droxidopa will ONLY work across the BBB and not outside of the brain. This is necessary to get the optimum amounts of NE in the brain, where it is needed and not outside of the brain where Droxidopa will be dopamine and possibly cause adverse effects.

To see an explanation from the full text of the study that explains the above in more technical terms, here is a quote:
    "We used an NE prodrug that readily crosses the blood-brain barrier (BBB). L-Threo3,4-dihydroxyphenylserine (L-DOPS) or droxidopa is a synthetic amino acid (34). L-DOPS is metabolized by L-aromatic amino acid decarboxylase within NE-containing neurons to yield NE."
By using Droxidopa (along with Carbidopa), the researchers were successfully able to substantially increase hippocampal NE concentrations in mice models of Down syndrome and therefore have greatly improved memory functions & capabilities.

The researchers are now hoping to be able to start clinical trials of Droxidopa on people with Down syndrome, so that it can be approved for use in people with DS. The hope of the Stanford researchers is that by giving Droxidopa and increasing NE concentrations, neurodegeneration may be able to be stopped, or slowed and therefore increase memory function & capabilities.

Their hope is also that it will be helpful to be used in people with Ds who are older and already have large amounts of degeneration and be able to target the still functioning parts of the neurons. Here is a quote from the full text of the study which Stanford researchers did (Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome.) that discusses the above,
"The most important implication of our work is that postsynaptic targets of degenerating neurons
may remain responsive and functional well after the presence of advanced disease in their presynaptic inputs. If so, treatments that target still-functional elements of neuronal circuits may restore circuit function. In particular, treatments targeted to restore the loss of NE inputs to the hippocampus may prove effective in enhancing cognition in people in whom these neurons are affected."
And, here is another interesting quote from the full text of this study. This quote below shows just how well their results were in the DS mouse models.
"Indeed, NE release from LC axons may play a defining role in cholinergic and serotoninergic
neurotransmission. Given the degeneration of these other neuronal systems in the Ts65Dn mouse as well as in DS and AD, it might be argued that dysfunction of the LC represents only one of several deficiencies and that rescuing NE concentrations would have no effect on cognition. Our data argue that this is not the case. Instead, they indicate that restoring NE neurotransmission is effective even when these other neurons are affected."
Another quote from the study, which summarizes what has been said above:
"In this study, two agents acted to restore contextual learning. In the case of L-DOPS, the drug is metabolized by LC terminals to produce NE......If this circumstance also applies to humans, restoring NE concentrations in the hippocampus may act to enhance contextual learning even in patients in which LC degeneration is advanced."
And one final quote from the study,
"Our findings suggest that enhancing NE neurotransmission may be useful in treating cognitive disability in DS. An important question is which age group to target. The murine studies reported herein suggest that young adults with DS, in whom pathology is present but not advanced, may be appropriate. If the status of LC neurons and their targets in mice mirrors those in humans, at this stage of the disorder postsynaptic adrenergic receptors will be present and responsive to
pharmacologically induced increases in brain NE concentrations. We envision a plan to test the efficacy of droxidopa in young adults with DS."
Now, the question is, do we supplement our children with L-DOPS, because of the positive outcomes of the study? It's a tough question.

I am one of those people who will look at a study and act upon the results. We've done it numerous times. That's why we give O Longvida Curcumin, Nutrivene-D, Ginkgo Biloba, etc. Because we've seen what the study says and we put the puzzle together - by doing this & giving this, an improvement was seen here, so let's do that!

From the research I have done so far, I see no harm in giving L-DOPS to increase NE levels. I see a lot of benefit.

Personally, I have a hesitancy with it still, because it is a drug and is a synthetic amino acid precursor. If you've been reading this blog for any length of time, you'll know that we have a hesitancy with taking drugs (hence the reason why O does not take Prozac, as is recommended by the Changing Minds Foundation). So, that is the only reason why and where my hesitation comes from.

I will continue to research L-DOPS/Droxidopa and ways to increase NE levels and share what I find, if I find anything else of interest. There are a few things I have taken down in a note to look at further as well, just in finding out other ways that NE deficiency is connected in Down syndrome.

There are some other thoughts and things I want to research in regards to possible ways to increase NE by using L-tyrosine, and using a natural DOPA decarboxylase inhibitor like EGCG, but that will have to wait for another day.


Photobucket

Friday, June 10, 2011

Nuts & Seeds to help Alzheimer's

This came through a Down syndrome list I'm on and I thought it would be helpful to share.

By Fiona Macrae
Last updated at 9:37 PM on 5th July 2010

Snacking on nuts could help keep the mind sharp into old age, research suggests.

A study has credited vitamin E - found in nuts, seeds and olive oil - with warding off Alzheimer's.

Pensioners with the highest amounts of the 'anti-ageing' vitamin in their blood were around half as likely to develop the devastating disease as those with the least vitamin E in their bodies.
Nuts are a rich source of Vitamin E which may ward off dementia. However, the Food Standards Agency warns that high doses of the vitamin can be harmful

Nuts are a rich source of Vitamin E which may ward off dementia. However, the Food Standards Agency warns that high doses of the vitamin can be harmful

The finding suggests that nuts and oils could provide a cheap and tasty way of keeping the mind healthy as the years advance.

Alzheimer's affects some 400,000 Britons and around 500 new cases are diagnosed every day.

The Swedish researchers measured vitamin E in samples of blood taken from 232 men and women. All were aged 80 or older at the start of the study and free of dementia.

After six years, 57 had developed Alzheimer's, the Journal of Alzheimer's Disease reports.

However, the disease was around half as common in those boasting the most vitamin E at the start of the study.

Previous research into the subject has produced conflicting results but the researchers believe this could be because it mainly focused on one sub-type of vitamin E, rather than looking at it as a whole.

Lead researcher Dr Francesca Mangialasche, of Stockholm's Karolinska Institute, said: 'Vitamin E is a family of eight natural components, but most studies related to Alzheimer's disease investigate only one of these components.

'We hypothesised that all the vitamin E family members could be important in protecting against Alzheimer's disease.

'If confirmed, this result has implications for both individuals and society, as 70 percent of all dementia cases in the general population occur in people over 75 years of age, and the study suggests a protective effect of vitamin E against AD in individuals aged 80-plus.'

She added that with previous research linking one particular form of vitamin E found in supplements with premature death, people would be better off getting a mix of the different forms of the compound from their diet.

A vegetable, fruit, nut and olive oil-rich Mediterranean diet could be particularly beneficial.

'Our findings need to be confirmed by other studies but they open up the possibility that the balanced presence of different vitamin E forms can have an important neuroprotective effect.'

The Food Standards Agency warns that high doses of the vitamin can be harmful and says that people should be able to get all the need from a balanced diet.




Photobucket

Tuesday, December 21, 2010

Vitamin E Supplementation

This study came through on of the DS listservs I'm on recently and I thought it would be a good study to share.

Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model.

Down syndrome (DS) individuals develop several neuropathological hallmarks seen in Alzheimer's disease, including cognitive decline and the early loss of cholinergic markers in the basal forebrain. These deficits are replicated in the Ts65Dn mouse, which contains a partial trisomy of murine chromosome 16, the orthologous genetic segment to human chromosome 21. Oxidative stress levels are elevated early in DS, and may contribute to the neurodegeneration seen in these individuals. We evaluated oxidative stress in Ts65Dn mice, and assessed the efficacy of long-term antioxidant supplementation on memory and basal forebrain pathology. We report that oxidative stress was elevated in the adult Ts65Dn brain, and that supplementation with the antioxidant vitamin E effectively reduced these markers. Also, Ts65Dn mice receiving vitamin E exhibited improved performance on a spatial working memory task and showed an attenuation of cholinergic neuron pathology in the basal forebrain. This study provides evidence that vitamin E delays onset of cognitive and morphological abnormalities in a mouse model of DS, and may represent a safe and effective treatment early in the progression of DS neuropathology.

You can view the full text of the study here.

The Ts65Dn mouse is a mouse model of Down syndrome. It has been very helpful in doing studies on supplements and gene information for Down syndrome.

Basically, this study shows that Vitamin E can help alleviate oxidative stress, which is known to be elevated in DS. And therefore help delay some of the cognitive abnormalities seen in these mouse models. The cognitive abnormalities seen in both mouse models and individuals with Ds are elevations of amyloid precursor protein (APP), which causes plaques & tangles on the brain. This leads to Alzheimer's. Increased oxidative stress is also the cause of many cognitive and metabolic problems in DS, so to be able to lower that, is extremely beneficial. This study also found that Vitamin E can help with the problems that APP brings with it.

So, all in all, Vitamin E has a lot of potential for people with DS and is an excellent antioxidant (which was already known). O takes Vitamin E in his Nutrivene-D because of it's antioxidant properties.


Photobucket

Saturday, October 2, 2010

31 for 21: B Vitamins Help Dementia

It is already known that B vitamins (especially B12) help people with Down syndrome, due to the overexpression of the SAM cycle by the CBS gene. This gene creates a "folate trap" and the body is not able to use the necessary folate that it needs. B12 helps with that, which in turn will help with the brain (because both low & high homocysteine affect the brain) and also certain other amino acid levels (such as glutathione).


LONDON (Reuters) - Daily tablets of large doses of B vitamins can halve the rate of brain shrinkage in elderly people with memory problems and may slow their progression toward dementia, data from a British trial showed on Wednesday,

Scientists from Oxford University said their two-year clinical trial was the largest to date into the effect of B vitamins on so-called "mild cognitive impairment" -- a major risk factor for Alzheimer's disease and other forms of dementia.

Experts commenting on the findings said they were important and called for larger, longer full-scale clinical trials to see if the safety and effectiveness of B vitamins in the prevention of neurodegenerative conditions could be confirmed.

"This is a very dramatic and striking result. It's much more than we could have predicted," said David Smith of Oxford's department of pharmacology, who co-led the trial.

"It is our hope that this simple and safe treatment will delay development of Alzheimer's in many people who suffer from mild memory problems."

Mild cognitive impairment (MCI) affects around 16 percent of people aged over 70 worldwide and is characterized by slight problems with memory loss, language or other mental functions.

MCI does not usually interfere with daily life, but around 50 percent of people diagnosed with it go on to develop the far more severe Alzheimer's disease within five years. Alzheimer's is a mind-wasting disease for which there are few treatments and no cure, and which affects 26 million people around the world.

Smith and colleagues conducted a two-year trial with 168 volunteers with MCI who were given either a vitamin pill containing very high doses of folic acid, vitamin B6 and vitamin B12, or a placebo dummy pill.

These B vitamins are known to control levels of an amino acid called homocysteine in the blood, and high blood levels of homocysteine are linked to an increased risk of developing Alzheimer's disease.

Helga Refsum, who also worked on the trial, stressed that vitamins were given in extremely high doses.

"This is a drug, not a vitamin intervention," she said.

The pills, called "TrioBe Plus" contained around 300 times the recommended daily intake of B12, four times daily advised folate levels and 15 times the recommended amount of B6.

Brain scans were taken at the beginning and the end of the trial to monitor the rate of brain shrinkage, or atrophy.

The results, published in the Public Library of Science (PLoS) One journal, showed that on average the brains of those taking the vitamin treatment shrank at a rate of 0.76 percent a year, while those taking the dummy pill had an average brain shrinkage of 1.08 percent.

People who had the highest levels of homocysteine at the start of the trial benefited the most from the treatment, with their brains shrinking at half the rate of those on the placebo.

Although the trial was not designed to measure cognitive ability, the researchers found those people who had lowest rates of shrinkage had the highest scores in mental tests.

Commenting on the study, Paul Matthews, a professor of clinical neurology at Imperial College London said that although the vitamins used are generally safe and inexpensive, the study "should not drive an immediate change in clinical practice"

"Instead, it sets out important questions for further study and gives new confidence that effective treatments modifying the course of some dementias may be in sight," he said.


Photobucket

Thursday, September 23, 2010

Researchers Find Link Between AD & Cataracts

This came through the DSTNI listserv which I'm on and I found it very fascinating. The Cataract problem & tendency to AD has been known for a long time. And the fact that there seems to be increased Amyloid-Beta protein in DS has also been known for a long time. So, to see the connection between the two is very interesting.



ScienceDaily (May 21, 2010) — A team of researchers has discovered that the protein that forms plaques in the brain in Alzheimer's disease also accumulates in the eyes of people with Down syndrome. The new findings in Down syndrome show that the toxic protein, known as amyloid-β, that causes Alzheimer's pathology in the brain also leads to distinctive cataracts in the eyes. The discovery is leading the researchers to develop an innovative eye test for early detection of Alzheimer's pathology in both disorders.

The research, led by Lee E. Goldstein, M.D., Ph.D., associate professor at Boston University School of Medicine and the Boston University Alzheimer's Disease Center, and Juliet A. Moncaster, Ph.D., associate director of the Molecular Aging & Development Laboratory, also at Boston University, was presented at the annual meeting of the Association for Research in Vision and Ophthalmology in Fort Lauderdale, Florida and reported in the May 20 issue of PLoS ONE. The research included investigators at the Brigham & Women's Hospital; Massachusetts Eye and Ear Infirmary; Massachusetts General Hospital; Harvard Medical School; Rush University Medical Center; Children's Hospital Boston, and the University of Washington, Seattle.

"People with Down syndrome develop symptoms of Alzheimer's-type dementia often by the age of 30," said Goldstein, senior corresponding author on the PLoS One article. "This is because they have an extra copy of a key Alzheimer's gene that leads to increased amyloid-β accumulation in the brain. We discovered that this same protein starts to accumulate very early in the lens of the eye, even in children, " explained Goldstein.

"The lens provides a window to the brain," said Moncaster, co-lead author of the study. "The lens can't clear protein deposits the way the brain does. Our findings show that the same amyloid-β protein that aggregates in the brain also accumulates in the lens and leads to these unusual cataracts in Down syndrome."

"The results are striking," added David G. Hunter, M.D., Ph.D., Ophthalmologist-in-Chief at Children's Hospital Boston and Vice Chairman of the Department of Ophthalmology at Harvard Medical School. "We have known that these cataracts are prevalent in people with Down syndrome and are sometimes seen at birth, but we never knew how they were related to the disorder -- now we know," said Hunter. "These distinctive cataracts appear only in people with advanced Alzheimer's disease and much earlier in Down syndrome."

According to the National Down Syndrome Society and the National Institute of Child Health & Development, Down syndrome is the most common chromosomal disorder and the leading genetic cause of intellectual disability. In the US, one of every 800 newborns and more than 400,000 people have Down syndrome. Although the disease is incurable, life expectancy for people living with Down syndrome has increased dramatically in recent decades -- from 25 in 1983 to 60 today.

"We are developing an eye scanner to measure amyloid-β in the lens," said Goldstein. "This approach may provide a way for early detection and monitoring of related pathology in the brain. Effective treatments for the brain disease in Down syndrome and Alzheimer's disease are on the horizon, and early detection is the key for successful intervention," he said. "The path to effective treatment is what drives our research."

Lead co-authors on the PLoS ONE publication are Juliet Moncaster (Boston University School of Medicine), Roberto Pineda (Massachusetts Eye and Ear Infirmary, Harvard Medical School), and Robert Moir (Massachusetts General Hospital, Harvard Medical School). Co-authors of the study are Suqian Lu, Mark Burton, Joy Ghosh and Anca Mocofanescu and Rebecca Folkerth (Brigham & Women's Hospital, Harvard Medical School), Maria Ericsson (Harvard Medical School), Stephanie Soscia and Rudolph Tanzi (Massachusetts General Hospital, Harvard Medical School), Richard Robb and David Hunter (Children's Hospital Boston, Harvard Medical School), Jerome Kuszak (Rush University Medical Center), and John Clark (University of Washington, Seattle). The corresponding author of the study is Lee Goldstein (Boston University School of Medicine and Boston University Alzheimer's Disease Center).

The five-year research effort was supported by the National Institutes of Health (National Institute of General Medical Sciences, National Institute on Aging), American Federation for Aging Research, Alzheimer's Association, American Health Assistance Foundation, Cure Alzheimer's Fund, National Disease Registry Interchange, Sun Health Research Institute, Florida Lion's Eye Bank, and an anonymous foundation. The investigators disclosed that at the time of the study Drs. Tanzi and Goldstein were scientific consultants to Neuroptix Corporation and with Dr. Moir to Covance, Inc. The authors reported no commercial research funding or other competing interests.

Journal Reference:

   1. Juliet A. Moncaster, Roberto Pineda, Robert D. Moir, Suqian Lu, Mark A. Burton, Joy G. Ghosh, Maria Ericsson, Stephanie J. Soscia, Anca Mocofanescu, Rebecca D. Folkerth, Richard M. Robb, Jer R. Kuszak, John I. Clark, Rudolph E. Tanzi, David G. Hunter, Lee E. Goldstein. Alzheimer's Disease Amyloid-β Links Lens and Brain Pathology in Down Syndrome. PLoS ONE, 2010; DOI: 10.1371/journal.pone.0010659



Photobucket

Friday, September 10, 2010

Niemann Pick Type-C & Proventigen

Chris Hempel, the mother of twin girls with Niemann Pick Type-C Disease (NPC), emailed to tell me about Proventigen. I'll give a little background first.


Chris is who we originally found out about Longvida Curcumin from. I'm so thankful we were able to run across their website and find it as it has helped so many in the DS community.

The Hempel's were using Longvida Curcumin for a slightly different reason, for their girls with NPC. NPC is also called Childhood Alzheimer's. It's a horrible, rare disease where children slowly begin to lose the ability to walk, talk, eat and live a normal life. These children die very young too and that's why it's called Childhood Alzheimer's disease. NPC is very rare and therefore there is no cure for it. Addi & Cassi's family do a lot of research and try all kinds of supplements and potential cures, so hopefully something will help these girls and therefore help others with NPC.

NPC is a genetic disease and is caused by accumulation (excess) of Cholesterol in almost every place of the child's body, but the most damaging part is the accumulation in the brain.

There are so many similarities between NPC and Alzheimer's Disease. And because there are so many similarities between AD and Down syndrome, it's very curious to know whether cholesterol plays a role in DS or whether families can find information through DS research for their kids with NPC. Unfortunately, not very much has been researched regarding cholesterol and DS. Although, there is something up with it, as cholesterol is typically high when bloodwork is done in DS. But, then again, Down syndrome is such a multi-faceted, complicated syndrome and there are so many factors that contribute to the syndrome, scientists have a lot of study!

So, back to Proventigen (click here to see it). Proventigen is a new product designed to support brain health. It contains Longvida Curcumin, Pomegranate Extract, N-Acetyl-Cysteine, Vit. B6, Folic Acid & Vit. B12.


It sounds like a very promising, good product. But . . . . . there's one problem that makes me slow to use it or recommend it for DS. It contains N-Acetyl-Cysteine (NAC), which has been seen to cause leaky gut and increased oxidative stress in DS. Neither of which are good things, especially when GI issues and high oxidative stress is already an issue in DS.

If it was all the other ingredients without NAC, I'd want to use it in a heartbeat! The combination of Longvida Curcumin & Pomegranate sound very hopeful. Both of those are excellent for promoting brain health! But, for now, unless other research shows up, we will pass on using Proventigen because of the concern of NAC.


Photobucket

Tuesday, September 7, 2010

New Research Regarding Alzheimer's & DS

A recent study was published in regards to the Amyloid Beta Protein and it's role in both Alzheimer's disease and Down syndrome. This protein is overexpressed in DS and is also responsible for the plaques and tangles which forms in AD patients.

This is one hope of Longvida Curcumin, to break up the plaques and tangles caused by APP. Curcumin is known to break up those plaques and tangles, but from what it appears it needs to be a very high dose. So, that is still in the works.

But what this study researched was what enzyme causes APP to produce plaques and tangles and a means to control that. While no drug or therapy that is safe has been found yet, this is non-the-less very interesting and noteworthy.

To see the abstract of the study, click here.

By Dr Cesar Chelala /New York

A finding by a team of Rockefeller University scientists led by Dr Paul Greengard, a Nobel laureate, throws light on an important feature of Alzheimer’s disease. The finding may result in better treatment for both this disease and for patients with Down syndrome. Better treatment for both diseases could improve the lives of millions of people worldwide.

Patients with both Alzheimer’s disease and with Down syndrome have an accumulation of a protein called beta-amyloid in their brains. The accumulation of this substance is believed to initiate the pathological changes (among them the plaque that builds up in the brains of people with Alzheimer’s) leading to brain dysfunction, cell death and dementia. The hallmark lesions (tangles and plaques) of Alzheimer’s disease are also present in all adults with Down syndrome after the age of 40, suggesting a shared genetic susceptibility to both.

Although it wasn’t known if beta-amyloid played a role in mental retardation, particularly in Down syndrome patients, the Rockefeller scientists worked under the hypothesis that it could have an effect. If this were true, they reasoned, lowering levels of beta-amyloid could result in an improvement of symptoms.

Dr Greengard and his collaborators found an enzyme (enzymes are proteins that speed up chemical reactions) that stimulates the production of beta-amyloid. In the new study, led by Gen He, a research associate in Greengard’s lab, the researchers showed that the enzyme stimulates production of beta-amyloid in cell lines, and that reducing it brings down beta-amyloid. That enzyme could thus be an important target for the development of new drugs against Alzheimer’s disease.

To test the hypothesis that increased beta-amyloid could be responsible for the symptoms of mental retardation, Dr Greengard and his colleagues tested a compound which is known to suppress the production of beta-amyloid in a mouse model with Down syndrome. Mice treated with this compound not only had a rapid reduction of beta-amyloid but also showed a significant improvement in their ability to learn to navigate a water maze. They were also able show some other signs of improved mental functioning. The control group used did not show any of these effects.

In another set of experiments, Dr Greengard and his colleagues developed a strain of mice that had a gene for Alzheimer’s. When they blocked the gene for the enzyme that increases the production of beta-amyloid, the animals didn’t develop plaque in their brains.

Reality in science is always more complex than anticipated, though. The compounds used to lower the levels of beta-amyloid have generally some serious toxic side effects. Only one of these compounds, the anti-cancer drug Gleevec, used to treat a rare form of leukaemia, was able to lower beta-amyloid without toxic side effects. The problem with Gleevec, though, is that it doesn’t remain in the brain long enough to treat either Alzheimer’s disease or Down syndrome. The importance of Gleevec, according to Dr Greengard, is that it may provide a model for developing new anti-beta-amyloid drugs.

The discovery of a new target for these drugs is a new and significant development in the treatment of Alzheimer’s disease and Down syndrome, both of which affect millions of people worldwide.  Only in the US, it is estimated that approximately 4mn Americans are affected by Alzheimer’s disease.

In what until recently had been an almost hopeless situation, the discoveries of Dr Paul Greengard and his colleagues shed a new light into what had been until now a rather dismal situation.



Photobucket

Friday, June 4, 2010

Choline Study in Down Syndrome Mice

This came across one of the Down syndrome email groups I'm on and I thought it was interesting. There are some families who already supplement Choline or Phosphatidylcholine (slightly different than "just" Choline) to their kids with DS. And they have noticed improvements. One big proponent of PC supplementation is the Changing Minds Foundation.

We do not supplement addition Choline or PC by itself. There is PC in Longvida though, so Osiyyah does get some in that way.


— More choline during pregnancy and nursing could provide lasting cognitive and emotional benefits to individuals with Down syndrome and protect against neurodegenerative conditions such as Alzheimer's disease, suggests a new Cornell study of mice.

The findings, published June 2 in Behavioral Neuroscience, could help lead to increasing the maternal dietary recommendations for choline (currently 450 milligrams a day during pregnancy, 550 milligrams for lactation), a nutrient found in egg yolks, liver, nuts and such vegetables as broccoli and cauliflower.

"We found that supplementing the maternal diet with additional choline resulted in dramatic improvements in attention and some normalization of emotion regulation in a mouse model of Down syndrome," said lead author Barbara Strupp, professor of nutritional sciences and of psychology. The researchers also found evidence for "subtle, but statistically significant, improvement in learning ability in the non-Down syndrome littermates."

In addition to mental retardation, Down syndrome individuals often experience dementia in middle age as a result of brain neuron atrophy similar to that suffered by people with Alzheimer's disease. Strupp noted that the improved mental abilities found in the Down syndrome mice following maternal choline supplements could indicate protection from such neurodegeneration "in the population at large."

Strupp and her co-authors tested Down syndrome model mice born from mothers fed a normal diet and those given choline supplements during their three-week pregnancy and three-week lactation period, as well as normal mice born from mothers with and without additional choline. The choline-supplemented mothers received approximately 4.5 times more choline (roughly comparable to levels at the higher range of human intake) than unsupplemented mothers.

At six months of age, the mice performed a series of behavioral tasks for about six months to assess their impulsivity, attention span, emotion control and other mental abilities.

In addition to dramatic improvements in attention, the researchers found that the unsupplemented Down syndrome model mice became more agitated after a mistake than normal mice, jumping repeatedly and taking longer to initiate the next trial, whereas the choline-supplemented Down syndrome model mice showed partial improvement in these areas.

"I'm impressed by the magnitude of the cognitive benefits seen in the Down syndrome model mice," Strupp said. "Moreover, these are clearly lasting cognitive improvements, seen many months after the period of choline supplementation."

Strupp noted that the results are consistent with studies by other researchers that found increased maternal choline intake improves offspring cognitive abilities in rats. However, this is the first study to evaluate the effects of maternal choline supplementation in a rodent model of Down syndrome. This is also one of the few studies that has evaluated offspring attentional function and effects in mice, rather than rats, Strupp noted.

Previous studies of humans and laboratory animals have shown that supplementing the diets of adults with choline has proven to be largely ineffective in improving cognition. "Although the precise mechanism is unknown, these lasting beneficial effects of choline observed in the present study are likely to be limited to increased intake during very early development," Strupp said.

The study, funded in part by the National Institutes of Health (NIH), was part of the dissertation of Jisook Moon, Ph.D. '06. Other Cornell collaborators included Myla Strawderman, research associate in nutritional sciences; David Levitsky, professor of nutrition and of psychology; May Chen '07 and Shruti Gandhy '07.

Strupp and collaborators have received additional NIH funding to study the neural mechanisms underlying the positive cognitive effects of perinatal choline supplementation observed in this study.



Photobucket

Monday, March 22, 2010

"Down syndrome patients could unlock mysteries of aging"

My aunt sent me this news article and I thought it was an interesting read. I knew pretty much about all this stuff already, but it was interesting to see it all in one spot.

Down syndrome patients could unlock mysteries of aging
By Liz Szabo, USA TODAY

Marybeth Solinski gets ready to blow out the candles on her 59th birthday cake last fall with her niece Sarah Gaziano, 22.


In 1950, when Marybeth Solinski was born, a diagnosis of Down syndrome was practically a death sentence.

Children with the condition often died before their 10th birthday.

PHOTOS: Marybeth Solinski turns 59 with Down syndrome
CAREGIVERS: Face new challenges as people with Down syndrome age

Yet Solinski, at 59, has outlived her parents. She has even joined AARP.

Her longevity illustrates the dramatic progress for people with Down syndrome. Thanks to better medical care, the average life expectancy for a child with Down syndrome is now 60 years, according to the National Down Syndrome Society, which estimates that about 400,000 people are living with the condition in the USA.

As they live longer, adults with Down syndrome — who have an extra copy of chromosome 21 — are teaching scientists about the genetic roots of aging, says Ira Lott, head of pediatric neurology at the University of California-Irvine School of Medicine.

Scientists today are searching this chromosome, which contains only about 200 of the body's roughly 20,000 genes, to learn why people with Down syndrome suffer disproportionately from some health problems, such as Alzheimer's disease, but are spared many others, such as heart attacks, strokes and certain types of cancer.

By studying adults with Down syndrome, researchers hope to find new ways to combat diseases of aging in the larger population as well, Lott says.

"It's an interesting detective story," says Lott, head of the science advisory board of the National Down Syndrome Society. "People with Down syndrome are unique when it comes to many aspects of aging."

Aging troubles start early

People with Down syndrome tend to age prematurely as they develop conditions such as menopause, brittle bones, arthritis, hearing loss, wrinkles and sagging skin about two decades earlier than usual, says Brian Chicoine, medical director of the adult Down syndrome center at Advocate Lutheran General Hospital in Park Ridge, Ill., the leading center of its kind.

"People say they seem to age overnight," says Dennis McGuire, director of psychosocial services at the same center. "They suddenly develop wrinkles and gray hair."

Solinski, for example, wears a brace on one leg and hearing aids in both ears, and she has had two corneal transplants. "She's more like a 79-year-old than a 59-year-old," says her sister, Lee Cornell of Illinois.

Yet researchers suspect that this unique genetic profile also protects people with Down syndrome from many common ailments. A growing number of researchers are asking:

•What protects their hearts?

Half of babies with Down syndrome are born with correctable heart defects, and most adults with Down syndrome are overweight with high cholesterol. Despite these risks, however, people with Down syndrome virtually never develop high blood pressure, heart attacks or hardening of the arteries, Lott says. Doctors are still trying to learn why.

•Why don't they get cancer?

Doctors once believed that people with Down syndrome didn't live long enough to develop cancer, says Sandra Ryeom, a researcher at University of Pennsylvania School of Medicine in Philadelphia

Yet, with the exception of a rare pediatric leukemia, even elderly adults with Down syndrome rarely develop solid tumors, such as those of the breast or lung.

Last May, Ryeom and her colleagues found genes on the 21st chromosome that inhibit the growth of blood vessels necessary for tumor growth. Getting an extra copy of these genes, and possibly others, may help the body keep cancers in check by depriving them of blood, she says.

Researchers already are trying to develop anti-cancer treatments based on genes found on chromosome 21, says Roger Reeves of Johns Hopkins University School of Medicine.

•What protects their eyes?

Although people with Down syndrome are at higher risk for cataracts, they rarely develop a form of blindness called macular degeneration, caused by an overgrowth of blood vessels in the retina, Ryeom says. Doctors suspect that the same genes that restrict blood vessel growth in tumors may also prevent abnormal blood vessel growth in the eye.

A link to Alzheimer's?

•Why do Down syndrome patients develop early Alzheimer's disease?

Adults with Down syndrome appear to develop the brain plaques and tangles characteristic of Alzheimer's disease very early in life — even as young as 3 or 4 years old. For decades, however, their brains also appear to repair and compensate for the damage, says scientist Elizabeth Head of the University of Kentucky's Sanders-Brown Center on Aging.

"Their brains may be clearing the plaques," says Head, who is now recruiting Down syndrome patients for a study on biomarkers of Alzheimer's. "As they get older, this protective process slows down."

By age 40 to 45, virtually everyone with Down syndrome has these plaques and tangles, although only 12% have dementia, Lott says. By age 65, up to 75% of people with Down syndrome have dementia.

Significantly, doctors have found a gene that increases the risk of Alzheimer's, called APP, on the 21st chromosome, Lott says. The gene, called amyloid precursor protein, is involved in the creation of the brain plaques seen in Alzheimer's patients. People who inherit mutated copies of these genes may develop Alzheimer's disease decades earlier than usual, says William Mobley, a neuroscience professor at the University of California-San Diego.

Yet not all people with Down syndrome succumb. One of Chicoine's patients lived to 83 without dementia.

Solinski, of Chicago, loves learning so much that she takes flash cards on vacation. She pores over children's encyclopedias and Nancy Drew novels. She is learning to cook, she says, to follow in the footsteps of her mother, who died in August at 92. And, she says, "I want to be a great reader like my father."

And Brooklyn resident Edward Barsky is still healthy and independent at 73, living in a group home and navigating public transportation on his own, says his sister, Vicki Ploscowe.

"He's still going strong," says Ploscowe, of Manhattan.

If researchers could learn what protects certain people, they might be able to develop a therapy to prevent Alzheimer's — both in those with and those without Down syndrome, Head says.

'No other population' like this

People with Down syndrome present doctors with a rare opportunity to watch the disease progress, Lott says.

"There's no other population where you can really study this," Lott says. Although some people without Down syndrome carry a gene that increases their risk of early dementia, "you don't know who in the general population is going to come down with sporadic Alzheimer's. With Down syndrome, you know that virtually 100% of them will have plaques."

For example, doctors don't yet know exactly how an extra copy of chromosome 21 causes or prevents disease, Lott says. It's possible that getting a 50% larger "dose" of a gene affects the body's susceptibility to a disease, he says. Or, it's possible that the extra genetic material simply makes the entire genome more unstable.

Reeves says he's grateful to the Down syndrome community for teaching scientists so much.

"If it weren't for people with Down syndrome having fewer tumors," Reeves says, "we never would have thought to look for anything like this."

Monday, January 18, 2010

Alzheimer's Disease & Down Syndrome: Linked?

There has been talk on some of the Down syndrome lists about new research which came out recently about Alzheimer's disease. They found that there is a sort of mosaicism found in patients with AD - a third 21st chromosome in some of their cells. Which may be responsible for all the extra amyloid plaques which are a large part of AD.

Are Down syndrome & Alzheimer's disease linked more closely than we realized? That is what it appears.

Alzheimer A{beta} Peptide Induces Chromosome Mis-Segregation and Aneuploidy, Including Trisomy 21; Requirement for Tau and APP.

Granic A, Padmanabhan J, Norden M, Potter H.

Eric Pfeiffer Suncoast Alzheimer's Center, Byrd Alzheimer's Institute, Florida Alzheimer's Disease Research Center, Department of Molecular Medicine, College of Medicine, School of Aging Studies, College of Behavioral and Community Sciences, University of South Florida, Tampa FL, 33613.

Monitoring Editor: Yixian Zheng Both sporadic and familial Alzheimer's disease patients exhibit increased chromosome aneuploidy, particularly trisomy 21, in neurons and other cells. Significantly, trisomy 21/Down syndrome patients develop early onset AD pathology. We investigated the mechanism underlying mosaic chromosome aneuploidy in AD and report that FAD mutations in the Alzheimer Amyloid Precursor Protein gene, APP, induce chromosome mis-segregation and aneuploidy in transgenic mice and in transfected cells. Furthermore, adding synthetic Abeta peptide, the pathogenic product of APP, to cultured cells causes rapid and robust chromosome mis-segregation leading to aneuploid, including trisomy 21, daughters, which is prevented by LiCl addition or Ca++ chelation and is replicated in tau KO cells, implicating GSK-3beta, calpain, and Tau-dependent microtubule transport in the aneugenic activity of Abeta. Furthermore, APP KO cells are resistant to the aneugenic activity of Abeta, as they have been shown previously to be resistant to Abeta-induced tau phosphorylation and cell toxicity. These results indicate that Abeta-induced microtubule dysfunction leads to aneuploid neurons and may thereby contribute to the pathogenesis of Alzheimer's disease.

**Full Text: http://www.molbiolcell.org/cgi/reprint/E09-10-0850v1

Quote from the full text:

"In sum, the data of this paper and previous results show that the AB peptide found at increased levels in both sporadic and familial Alzheimer's disease interferes with mitosis and chromosome segregation, thus leading to trisomy 21 mosaicism and other chromosome aneuploidy. The implication of the results is that MT disruption leading to cell cycle, chromosome mis-segregation, and other cytoskeletal defects in neuronal precursor cells may underlie many of the neurotoxic aspects of Alzheimer's disease. The findings also suggests that novel approaches to diagnosis and treatment directed at detecting and preventing disruption of MT function and/or the development of chromosome aneuploidy with age may be successful against Alzheimer's disease and possibly other age associated disorders."

This is one main reason Longvida Curcumin has captured so much attention in the Down syndrome community. It is an excellent antioxidant, but it has the potential to clear those nasty amyloid plaques from the brain. That shows much promise!

Qadoshyah

Monday, September 7, 2009

Loads of Information about Longvida Curcumin

Alright, well, this is the post I've wanted to get up for awhile. All the loads of information I've gotten about Longvida and continue to forward to folks who are interested in more information about this. So, here goes . . .

Why is Longvida Curcumin different & better than just plain 'ole Turmeric?

Longvida is based on a patent-pending invention Verdue Sciences license from UCLA that was developed by a group in the Alzheimers center there. As you probably know, curcumin has tremendous promise as a potential Alzheimer's treatment and anti-inflammatory and has at least 10 different neuroprotective effects, but its not water soluble or bioavailable via oral dosing. What we have done is scale up this technology that coats curcumin microparticles with an amphiphilic/lipophilic coating. The support for its absorption is based on pK data and research from UCLA showing it reverses amyloid beta, tau tangles, neuroinflammation, and neurooxidation in Alzheimer's models. The formula was selected from hundreds of mainly lipid-based formulas that were tried and this one was selected based on bioavailability data in animals and humans. Of particular interest is what we believe to be the highest brain curcumin levels in animals that have been achieved via oral dosing. All the ingredients are commonly found in the food chain and are legal dietary supplement and food additive ingredients.

The other ingredients in Longvida Curcumin are a fatty acid & lecithin. Why are there two other ingredients in it? They are needed for optimum absorption.

What is the cost of Longvida Curcumin & where can it be ordered?

Because Longvida Curcumin is so new and not readily available through other companies yet, the pricing is only introductory pricing, so will be changing once it is widely available.

Longvida can be ordered by contacting Blake Ebersole at:

Blake Ebersole
1250 E. Conner Street
Noblesville, IN 46060 USA
+1.317.776.3600
bebersole@vs-corp.com

www.longvida.com
*Note: Longvida's website doesn't have much information on it yet, but it should be up shortly!

Is there any research about Longvida?

Yes, there is. I asked Blake Ebersole this question back when I was first looking into this in May '09. He sent me the powerpoint that was given at Neuroscience in November and also gave me another pdf from the UCLA Alzheimer's researcher who I have been in contact with (Sally Frautschy). I haven't looked at what he sent yet, but I will be going through it.

Because the data regarding this formula has not been published yet, I cannot post or give any of the above info that he sent me out. UCLA is in the process of putting the manuscript together and the journals won't publish data that has been made public elsewhere. But, you are welcome to email Blake and he should be able to pass on the research that he has.

I also have several studies that show all the benefits of Curcumin. I will try to post those up at another time.

What is the dosing?

The dosing for Longvida Curcumin is not a clear issue, because it is so new and has such limited use in people. I asked about how the dosages some of the other children who are on this are taking and this is what I was able to find out: a 3 yr old taking 6000mgs/day, 4 yr old twins - 2-4g [2000-4000mgs]/day, two teenagers (1000, 4000 & 6000mgs per day),

I also emailed Chris Hempel (mom of twin girls with Niemann Pick Type C Disease who we originally found out about Longvida from) and asked her a few questions regarding the dosages her daughters take and all. She gives them 6 capsules a day (3000mgs) each and they are currently 5 years old.

We give my brother 2000mgs/day. Initially we started at 500mgs/day for a week, then increased to 1000mgs/day and stayed at that for 7 weeks. We then increased to 1500mgs/day for a week and finally went to our goal of 2000mgs/day. Whenever you start something new, you want to start slow and increase it slowly so that it doesn't get overwhelming.

Several other parents of children with DS are using 1000mgs, 1500mgs, and even 2000mgs. Dr. Leichtman has recently started using this with his patients and he is using the dosage of 1000mgs/day for the time being.

How many people are using this?

To my knowledge, there are around 100 families/individuals using this with their child/children with Down syndrome. There are probably others who are using this with their kids/adults with DS that I am not aware of. If you're using this with your kid, would you mind sending me an email or leaving a comment here? That would be great, since all the more information we have about this the better, since it is all SO new.

Information from Sally Frautschy, professor of Neurology from UCLA (& she also helped develop Longvida):

I emailed her the log of what we have seen with Osiyyah, as I have been in contact with her since before we started Longvida. She was glad to know that we have seen changes and she also said she was surprised that we had seen all those improvements at such a low dose. I was surprised as well, as I really didn't expect to see any changes. But, what we saw (& see) is so amazing, it has to be from the Longvida.

She said that there is approximately 250mgs of Curcumin per 1000mgs. The other ingredients in Longvida are the fatty acid and lecithin. The fatty acid and such are necessary to help make the Curcumin bioavailable.

She also suggested giving the full Curcumin dose once a day, at night or before bedtime. This will help so that the Curcumin can do it's optimum, while the child is resting and it's body isn't "working" on anything else.

But, it's also because it will build up in fatty tissues, like the brain, so it doesn't need to be given more than once a day.

She also recommended giving a higher dose for 7 days once a month. I am considering doing that with Osiyyah. He will be taking 2000mgs/day and then for 7 days a month go up to 3000mgs/day.

Question 1 - "What do you think an ideal dose of Longvida would be for a child with DS (let's say age 4)?"

Sally said he best guess is that a baseline for a small child would be 250-500mg of Curcumin. Which would be 1250-2500mg of Longvida. We are at the 2000mg/day mark (after being at 1500 for the past week), and just may increase to 2500mg. We will see how things go.

Question 2 - "You suggested to increase the dose for 7 days a month. Is that to help it (Curcumin) build up in the fatty tissues?"

Sally said it is to help build up the dose in fatty tissues, but it is more specifically to clear amyloid from the brain. She said the dose for clearing amyloid appears to be higher.

Question 3 - "How much of a higher dose do you think would be necessary to clear the amyloid from the brain?"

Sally said in a study using mice getting levels of 0.5 uM in plasma is high enough to reduce the size of preexisting plaques in mice in 7 days. She said that seems to be a good target.. She would suggest giving a young child 1000mg Curcumin (which is equivalent to 5000mgs Longvida).

Yet more information from Prof. Frautschy regarding Longvida:

"CURCUMIN IS NOT LIKELY TO PROVE TO BE A BLOOD THINNER. The in vitro data arguing that curcumin can be a blood thinnner has not panned out in vivo. It had the opposite effects in our patient study. IN terms of the blood thinning properties of curcumin, there is no data in vivo to support that curcumin acts that way, nothing at all like aspirin. It is highly unlikely since it doesn't impact COX-1 directly. However, EPA from fish has "blood thinning" (as demonstrated by restriction of platelet aggregation) properties and DHA may impact that to a lesser extent. . I suggest that when on these supplements to get a clotting tests after 3 months on the supplement, in case there is an unforeseen interaction of DHA/EPA and curcumin. If there is easy bruising when one bumps themselves, make sure to go get clotting tested. My guess is that if one is on a high dose of DHA, then this would lower the dose of NSAID one needs (curcumin or whatever), but again , we don't know the perfect combination because NIH and pharma will not fund the proper number experiments needed to do to answer these important questions.

INTERACTIONS: Don't know about interactions of curcumin with ginkgo biloba."

Qadoshyah

Related Posts with Thumbnails